Walvax Biotechnology Co., Ltd. (300142.SZ) Latest Company News

Oct 15, 2026, 07:22 UTC
Chengdu Womusen Biotechnology Co., Ltd. was established as an indirectly wholly owned subsidiary of Walvax Biotechnology, with business scope including integrated circuit sales.
Source:
- finance.sina.cn
Sep 30, 2026, 09:47 UTC
On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.
Source:
- finance.ifeng.com
Sep 10, 2026, 11:48 UTC
China's National Medical Products Administration granted a drug registration certificate to Yuxi Walvax for its COVID-19 mRNA vaccine, approved for people aged 18 and above.
Source:
- finance.sina.cn
Sep 8, 2026, 07:47 UTC
Walvax Biotechnology announced that its nine-valent HPV vaccine is currently in Phase III clinical trials.
Source:
- finance.sina.cn
Aug 28, 2026, 09:51 UTC
Walvax Biotechnology announced its first-half 2026 results: net profit attributable to shareholders was 54.1922 million yuan, up 25.56% year-on-year.
Source:
- finance.sina.cn
Aug 27, 2026, 12:13 UTC
Walvax Biotechnology announced that its 2026 private placement of shares to specific targets has been accepted for review by the Shenzhen Stock Exchange.
Source:
- finance.sina.cn
Aug 15, 2026, 12:18 UTC
China Haisum Engineering Co., Ltd. won the bid for the energy and carbon management platform project of Yunnan Walvax Biotechnology Co., Ltd.
Source:
- finance.sina.cn
Aug 3, 2026, 12:08 UTC
Walvax Biotechnology plans to issue no more than 208 million A-shares to specific investor Tengyun Xinwo, with subscription amount not exceeding 2.203 billion yuan, to supplement working capital; after the issuance, Tengyun Xinwo will become the controlling shareholder and Huang Tao the actual controller.
Source:
- finance.sina.cn
Jul 23, 2026, 11:13 UTC
Watson Bio's subsidiary Yuxi Zerun Biotechnology received a drug registration certificate from the Tanzania Medicines and Medical Devices Authority for its bivalent HPV vaccine WALRINVAX, granting marketing authorization in Tanzania.
Source:
- finance.sina.cn

300142.SZ

Chengdu Womusen Biotechnology Co., Ltd. was established as an indirectly wholly owned subsidiary of Walvax Biotechnology, with business scope including integrated circuit sales.

On the last trading day before China's National Day holiday, Chinese pharmaceutical stocks surged broadly, with the pharma index closing up 2.73% and the innovative drug index up 3.42%, while semiconductors fell 2.75%.

China's National Medical Products Administration granted a drug registration certificate to Yuxi Walvax for its COVID-19 mRNA vaccine, approved for people aged 18 and above.

Walvax Biotechnology announced that its nine-valent HPV vaccine is currently in Phase III clinical trials.

Walvax Biotechnology announced its first-half 2026 results: net profit attributable to shareholders was 54.1922 million yuan, up 25.56% year-on-year.

Walvax Biotechnology announced that its 2026 private placement of shares to specific targets has been accepted for review by the Shenzhen Stock Exchange.

China Haisum Engineering Co., Ltd. won the bid for the energy and carbon management platform project of Yunnan Walvax Biotechnology Co., Ltd.

Watson Bio's subsidiary Yuxi Zerun Biotechnology received a drug registration certificate from the Tanzania Medicines and Medical Devices Authority for its bivalent HPV vaccine WALRINVAX, granting marketing authorization in Tanzania.